Clinical Trial Update: Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting results for a study of peginterferon alfa-2a, ribavirin, and daclatasvir with or without BMS-650032 in hepatitis C; results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BMS-650032
• Daclatasvir (daclatasvir)
• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2016-05-27